1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001

SEEGENE, INC.

(A096530)
  Report
End-of-day quote Korea Stock Exchange  -  05-25
43200.00 KRW   +0.58%
05/25Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic
AQ
05/13Seegene reports first quarter 2022 financial results
AQ
04/26Seegene unveils world's first commercialized '3 Ct' PCR assay
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

01/19/2022 | 07:00am EDT

Seegene Inc. announced the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is expected to reduce the total turnaround time to a third and expand testing capacity up to 3 times for hospitals and laboratories without additional instruments or compromise on accuracy. Reduction of the turnaround time was attributable to two primary reasons: 1) the application of a novel enzyme developed by Seegene, which reduces PCR process time to half. 2) Seegene's innovative extraction-free method, which can let Allplex™ SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests. This drastically reduces the total turnaround time for each result. As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour. The Allplex™ SARS-CoV-2 Fast PCR Assay targets three COVID-19 genes––E, RdRP, and N–– to reliably detect COVID-19 regardless of the variants. According to clinical research conducted by 17 laboratories in seven countries, this assay showed the same or better accuracy for the COVID-19 detection as other diagnostic tests available in the market.


© S&P Capital IQ 2022
All news about SEEGENE, INC.
05/25Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic
AQ
05/13Seegene reports first quarter 2022 financial results
AQ
04/26Seegene unveils world's first commercialized '3 Ct' PCR assay
AQ
04/26Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay
CI
04/06Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval
CI
03/17Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
AQ
03/04Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
CI
03/04Seegene, Inc. authorizes a Buyback Plan.
CI
03/02Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
AQ
02/24Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era
AQ
More news
Financials
Sales 2022 1 133 B 0,90 B 0,90 B
Net income 2022 371 B 0,29 B 0,29 B
Net cash 2022 657 B 0,52 B 0,52 B
P/E ratio 2022 6,08x
Yield 2022 1,91%
Capitalization 2 228 B 1 764 M 1 764 M
EV / Sales 2022 1,39x
EV / Sales 2023 1,93x
Nbr of Employees 928
Free-Float 67,9%
Chart SEEGENE, INC.
Duration : Period :
Seegene, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 43 200,00 KRW
Average target price 57 000,00 KRW
Spread / Average Target 31,9%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jin-Soo Choi President & General Manager-Management
Kyung-O Min President & Head-Research
Min-Chul Lee President, Head-Research & Development
Ho Lee President & Head-Sales
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-29.18%1 747
EXACT SCIENCES CORPORATION-37.77%8 521
BGI GENOMICS CO., LTD.-24.50%4 135
GUARDANT HEALTH, INC.-63.52%3 719
IOVANCE BIOTHERAPEUTICS, INC.-22.58%2 323
BEIJING STRONG BIOTECHNOLOGIES, INC.-17.15%1 435